Tirzepatide
Typical Dosage
1-2 mg/day
Administration
Injection
Half-Life
~5 days
Mechanism of Action
Diabetes and obesity research|GIP/GLP-1 dual agonist pharmacology|Weight-loss outcomes|Cardiometabolic studies
Research Protocol Summary
Evidence Level
Human Clinical / Marketed
Species Studied
Human • Mouse • Rat
Administration Schedule
2-3 times weekly
Studies
Research Availability
Individual PubMed records have not been mapped for this entry yet. Use the linked PubMed search to review the current literature directly.
Related resources
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Loading approved insights…